A Multi-Center, Randomized, Double-Blind, Parallel Group,Active-Controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients with Chronic Heart Failure and Reduced Ejection Fraction
Description of Research
The purpose of this study is to evaluate whether LCZ696, when compared to enalapril, is safe and effective in preventing cardiovascular death or heart failure hospitalization.
LCZ696 is an investigational drug that is being tested for its ability to treat chronic heart failurewith reduced ejection fraction.
For patients being treated with medications for chronic heart failure and reduced ejection fraction (a decreased amount of blood being pumped out of your heart.) This study will try to find out if LCZ696 is safe and has beneficial effects when added to conventional heart failure therapy in patients with chronic heart failure and reduced ejection fraction.